Danish drugmaker Novo Nordisk said it plans to make its new obesity pill available through telehealth platforms like Ro and WeightWatchers once it gets U.S. approval, Bloomberg News reported on Friday.
The pill uses the same active ingredient as Novo’s popular weight-loss injections Ozempic and Wegovy, and could be available in early 2026, the report said.
Novo did not immediately respond to a Reuters request for comment.
The company is also considering a subscription model where patients commit to six or 12 months of treatment at a discounted price, the report added.
